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A 27-year-old Puerto Rican man presented to Yale-New Haven Hospital with a six-week
history of left-sided headache, diplopia, and drooping of the left side of his face.
Cerebrospinal fluid examination showed a lymphocytic pleocytosis and a CT scan of the
brain revealed an unusual intrapontine mass lesion requiring systemic antifungal therapy. This
case emphasizes many of the diagnostic and therapeutic considerations required for effective
therapy of fungal disease in the central nervous system.
CASE PRESENTATION
This 27-year-old Puerto Rican male hospital dietary worker was well until six
weeks prior to admission when he noted the gradual onset of headache in the left
temporal region, diplopia, and weakness of the left side of his face. The headache
was constant and was not relieved by aspirin. The patient denied antecedent trauma,
fever, drug abuse, migraine, weight loss, underlying medical illnesses, or contact
with animals or birds. Physical examination revealed an oriented, afebrile patient
with weakness of cranial nerves V, VI, VII, VIII, and XII on the left, a pronator
drift of the right arm, and an extensor plantar response of the right great toe. The
hematocrit was 44.7 gms/dl, white blood count 8600cells/Al with a normal differen-
tial. Urinalysis was normal. Lumbar puncture revealed an opening pressure of 230
mm of water, protein of 34 mg/dl, glucose 65 mg/dl with a cell count of 80
nucleated cells (93 lymphocytes and 7 monocytes) and 9 red blood cells. An India ink
preparation on the CSF was negative. Cytologic examination of the CSF revealed
numerous mononuclear cells and Grade II astrocytes. Computerized axial
tomography ofthe brain (CT scan) (Fig. 1) revealed a pontine mass lesion after twice
the usual dose of radiocontrast dye was injected. Culture of the CSF revealed Cryp-
tococcus neoformans. The CSF cryptococcal antigen was positive at 1:16 dilution
and the CSF cryptococcal antibody was negative (1:2).
DISCUSSION
DR. DAVID L. COLEMAN (Infectious Disease Fellow): This patient's neurologic find-
ings were compatible with an intrapontine lesion producing cranial nerve palsies and
slight right arm weakness. The CSF culture did not become positive for C. Neofor-
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" FJ ; 1' FIG. 1. Brain CT scan demonstrating
pontine mass lesion (arrow) enhanced by
contrast media.
mans for ten days. After the CT scan, which test would be advisable to discriminate
between a neoplastic and an infectious process?
DR. VINCENT T. ANDRIOLE (Professor ofMedicine, Co-Chief, InfectiousDisease Sec-
tion): Perhaps an arteriogram would be helpful in discriminating between tumor and
a central nervous system lesion due to Cryptococcus neoformans. It really should
not be much different than trying to separate a renal carbuncle from a renal
neoplasm. One would expect the renal carbuncle to have vessels located around the
circumference and to be decidedly less vascular within the mass. Tumors are either
hypovascular or hypervascular but not both. If the pontine lesion were due to a
neoplasm, one would not expect to see peripheral hypervascularity and central
avascularity as is seen with a carbuncle.
DR. FRANK J. BIA (Assistant Professor ofMedicine and Laboratory Medicine): Dr.
Andriole is making an important point. Ifthis patient's neurologic deficit is due to a
cryptococcal mass lesion, or what is sometimes called a toruloma, one would really
expect very little vascularity. The histologic description of a cryptococcal toruloma
is that of a mass of expanding organisms with minimal inflammatory reaction
around them.
DR. COLEMAN: Two aspects of this particular case warrant special consideration.
First, how do we treat the patient with cryptococcal meningitis? Second, what is the
diagnostic and therapeutic strategy in the unusual patient with a CNS mass lesion in
association with cryptococcal meningitis?
DR. ANDRIOLE: Although many physicians are currently employing a combination of
amphotericin and 5-fluorocytosine, I believe the evidence to support the use of com-
bination chemotherapy is still inconclusive. But before dealing with that issue, let me
try to address the question ofsurgical intervention for cryptococcal torulomas. One
ofthe first patients that we investigated with cryptococcal disease had acryptococcal
toruloma. We learned that the surgical prognosis ofpatients with mass lesions from
this disease is often directly related to the location of the lesion. In my view, the
surgical approach to apontine lesion in the patient presented by Dr. Coleman would
be fraught with potential complications and would be risky.
DR. RICHARD K. ROOT (Professor ofMedicine, Co-ChiefInfectious Disease Section):
What about the use of steroids in this circumstance? I wonder whether steroid
therapy would allow a little time to reduce the edema around an inflammatory lesion
while antimicrobial therapy is instituted.
DR. ANDRIOLE: Steroids may slightly reduce the inflammatory reponse around the
mass lesion. The use of corticosteroids is primarily empiric and not clearly sup-
ported on the basis of presently available literature. It would seem to me that the
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lymphocytic response is desirable, in that lymphocytes may have some potential role
in combating the infection. Conceivably, steroids might inhibit this host response. I
probably would have started the patient on amphotericin therapy alone.
I think this is a good time to review the available data which supports the use of
combination therapy versus amphotericin alone. The primary series which com-
pared amphotericin therapy alone versus amphotericin and 5-fluorocytosine ap-
peared in the New England Journal ofMedicine [1], and in my view was premature
in its conclusion that combined fluorocytosine-amphotericin B therapy is the
regimen of choice in cryptococcal meningitis. While the combination regimen may
be most appropriate, I do not believe that this study conclusively demonstrated this
fact. Also, that paper reported a group of patients with cryptococcal meningitis and
not cryptococcal toruloma. The authors treated patients with amphotericin B in
doses (0.4 mg/kg of body weight daily) which proved to be ineffective in our
preliminary studies 20 years ago.
DR. ROOT: But what was the cure rate in that group of patients?
DR. ANDRIOLE: I do not remember the exact cure rate, but it was low. This dose rarely
eliminated viable cryptococci from the cerebrospinal fluid. An additional problem
with the combined therapy study is that they used this low dose of amphotericin B
alone for four weeks and then increased the dose of amphotericin B to higher levels
every other day for the final two weeks of therapy. In contrast, the combination
regimen included 5-fluorocytosine (150 mg/kg of body weight per day) and 0.3
mg/kg of body weight of amphotericin B daily for six weeks. The patients who
could not tolerate the combination regimen were removed from the combination
group and were then treated with amphotericin B alone at the higher dose. Those pa-
tients were not added to the "amphotericin alone" group. However, if they are added
to this group, the difference between the two regimens is no longer statistically
significant.
Specifically, 32 patients were entered into the amphotericin B treated group and
five of these patients did not adhere to the protocol. Of 27 adherent amphotericin B
treated patients, 11 (41 percent) were cured or improved. Of the five who did not
adhere to the protocol, but who'were treated with amphotericin B alone, four were
cured or improved. Thus, 15 of 32 (47 percent) amphotericin B treated patients were
cured or improved. In contrast, 34 patients were entered into the combination treat-
ment protocol and ten did not adhere, of whom seven couldn't because of 5-fluoro-
cytosine toxicity. This means that 20 percent of patients on combination treatment
developed toxicity sufficient to require discontinuing the 5-fluorocytosine. Of the 24
adherent patients, 16 (67 percent) were cured or improved. Furthermore, seven of
the ten non-adherent patients who were started on combination therapy but who
were continued on amphotericin B treatment alone in increased doses were cured or
improved. Therefore, if we examine all patients treated with amphotericin B essen-
tially as the major antifungal agent, favorable responses were obtained in 22 of 39
(56 percent) as compared with 16 of 24 (67 percent) essentially treated with combina-
tion therapy (chi square = 0.29, p = >0.5). Thus, while the combination regimen
has been tentatively accepted at most centers, I believe that the data presented in this
study are not conclusive enough to justify the statement that combination therapy is
the regimen of choice in cryptococcal meningitis.
DR. JASON DAVID GAINES (Assistant Clinical Professor of Medicine): What about
arguing that with the combination regimen we can get by with lower doses of am-
photericin and spare the patient some nephrotoxicity?
DR. ANDRIOLE: That is an excellent question, Dr. Gaines. We encountered significant
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renal and hematologic toxicity in the two patients we have treated with combination
therapy and that was more impressive than the toxicity we observed in the 70 pa-
tients treated with amphotericin alone. One possible explanation for this apparent
increased toxicity in patients on combination therapy may be related to the
mechanism ofaction ofthe two drugs in the combination. The cryptococcal cell con-
tains cytosine permease which allows 5-fluorocytosine to enter the fungal cell,
whereas human cells were thought to be relatively resistant to penetration by
5-fluorocytosine. Once 5-fluorocytosine enters the cell it is deaminated by cytosine
deaminase to 5-fluorouracil which is then converted to uridine monophosphate by
uridine 5-monophosphate pyrophosphorylase. In fact, five patients have been
reported who have detectable 5-fluorouracil levels in their serum while on the drug.
These were patients undergoing simultaneous treatment with amphotericin.
Another problem with 5-fluorocytosine is the development of resistance to this
agent. For example, one of the problems in treating Candida infections with
5-fluorocytosine is that resistance develops quite rapidly. The development of in
vitro resistance can occur at several possible steps. If resistance develops at the level
of cytosine permease then one can simply increase the dose to produce a therapeutic
effect. However, if resistance is due to block at the 5-monophosphate
pyrophosphorylase level, increasing the dose of the 5-fluorocytosine will not result
in benefit. Unfortunately, the major mechanism of Candida resistance to
5-fluorocytosine is at the uridine 5-monophosphate pyrophosphorylase level. I think
we are going to see higher levels of 5-fluorouracil and a higher incidence of
hematologic toxicity when the combined regimen is used as opposed to amphotericin
B alone. On careful review of the combination therapy study, I note that 30 percent
of the patients who received combination therapy had side effects. I personally
believe that we need further studies to document the safety and equivalent efficacy
ofcombination chemotherapy for treatment ofcryptococcal meningitis before alter-
ing what, in my experience, has been a reasonably safe and very effective modality
of treatment, namely, amphotericin B.
DR. ROOT: I think another point in Bennett's paper is that marrow suppression is
much more likely to occur when the patient has pre-existent bone marrow abnor-
malities.
DR. ANDRIOLE: I recall a patient at the VA Medical Center with pulmonary cryp-
tococcosis. We treated the patient with four weeks of combination chemotherapy
and he experienced a marked rise in his BUN and creatinine. I haven't seen a similar
rise in BUN or creatinine in treating many patients with amphotericin B alone for
several different indications. In addition, the patient developed cryptococcal men-
ingitis and anemia while on combination therapy and was subsequently cured with a
higher, and more conventional dose of amphotericin B alone.
DR. ROOT: Do you feel that mannitol has any role in reducing amphotericin
nephrotoxicity?
DR. ANDRIOLE: No, I do not.
DR. ROOT: Dr. Andriole, do you feel that concommitant administration of bicar-
bonate will reduce amphotericin nephrotoxicity?
DR. ANDRIOLE: Yes, we have excellent evidence in an experimental animal model of
amphotericin B nephrotoxicity. We found a marked reduction in nephrotoxicity
with administration ofsodium bicarbonate and amphotericin in rats and there is one
published study which suggests it is similarly useful in humans [5,6].
DR. BIA: Dr. Andriole, in your experience, how often do patients with cryptococcal
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meningitis have associated mass lesions in the central nervous system, and is this
considered an indication for surgery?
DR. ANDRIOLE: I have seen only two patients with documented cryptococcoma in
association with meningitis. In the two patients that I have seen with cryptococcal
mass lesions, one of them was treated with amphotericin B alone (0.8 mg/kg/day)
and did well with nearly complete resolution ofthe neurologic deficit. The other pa-
tient died three days after transfer to the National Institutes of Health. Since cryp-
tococcal torulomas are rare, it is difficult to perform a comparative study ofmedical
andsurgical treatment for this complication ofcryptococcal meningitis. Therefore, I
think in this particular case we are left with a difficult clinical decision. My own
opinion would be to begin a course of medical therapy which would consist of am-
photericin alone and evaluate the patient four weeks after initiation of therapy. If
the CT scan and clinical picture suggests resolution, I would not consider surgery
necessary. However, if the patient were clinically symptomatic with evidence either
by culture or serology of continued infection, I would continue treatment. I would
consider surgery for this patient if he began to deteriorate on medical therapy. Ob-
viously I would be influenced by theneurosurgeon's opinion as to the relative risk of
a surgical approach to this difficult area of the brain.
DR. ROOT: I agree with the treatment regimen that you have outlined. It would also
seem reasonable to place this patient on a brief course of corticosteroid therapy to
potentially reduce the cerebral edema seen with this lesion.
DR. ROBERT BALTIMORE (AssistantProfessorofPediatricsandEpidemiology): Ithink
that measurement of 5-fluorocytosine levels in the serum would be an important
means of following patients on combination therapy and might avoid some of the
problems that you have addressed. Can we measure 5-fluorocytosine levels here at
Yale-New Haven Hospital, and if so what is your feeling about their utility?
DR. ANDRIOLE: We attempted to set up a method for measurement of
5-fluorocytosine levels some years ago. However, we found our method to be ex-
tremely unreliable and it required several days of work. We therefore discontinued
its measurement.
DR. COLEMAN: Dr. Andriole, it was my understanding that the treatment success of
the combination regimen ofamphotericin and 5-fluorocytosine cited by Bennett was
comparable to earlier work that you published.
DR. ANDRIOLE: Yes, that is true; however, you should realize that when we initially
established what is now considered a high-dose amphotericin regimen, 0.8
mg/kg/day, every other day, we had a number of treatment failures at lower doses.
This is why I feel a relatively conservative approach to the acceptance of the com-
bination regimen is warranted.
DR. ATKINS: One of the objectives of the collaborative study by Dr. Bennett was to
attemptto shortenhospitalization inpatients withcryptococcal meningitis. I wonder
ifyou could comment on the treatment success rate using six weeks ofhigh-dose am-
photericin alone.
DR. ANDRIOLE: I believe you have cited the real potential value of combination
chemotherapy if, in fact, it were shown to be equivalent to the conventional am-
photericin dose. The only study I'm aware of was a study of patients with diverse
fungal infections which was done at Vanderbilt several years ago [6]. This study
employed aten-weekregimen ofamphotericin, which was given in a daily dose suffi-
cient to provide peak serum levels at least twice those necessary for in vitro inhibi-
tion oftheinfecting fungus, and showed excellent results. However, I would caution
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against strict extrapolation to this patient because this study was conducted on a
group of patients with a variety of different organisms and with various stages of
disease. Furthermore, the concept behind this study was that lower doses, given for
a longer period (ten weeks) might be as effective as higher doses given for a shorter
period (six weeks). In the patients that we have treated anywhere from three weeks
to six months oftherapy (mean: seven weeks) was required to eradicate cryptococcal
meningitis. Therefore, I think a shorter course regimen would be ofpotential benefit
in a select group of patients. However, I would be reluctant to advocate its use in all
patients with cryptococcal meningitis. We used the mouse inoculation technique as a
means of following patients in the 1950s and 1960s prior to the availability of cur-
rent serologic methods. I still believe the mouse inoculation method is a sensitive in-
dex oforganism load in these patients. We found that small members ofviable cryp-
tococcal organisms would kill a mouse within two weeks after inoculation. Of
course, if one could show an equivalent benefit from combination therapy as from
longer courses ofamphotericin alone, we will have made a major impact on therapy
of this disease.
A PHYSICIAN: Does intrathecal amphotericin have any role in treatment of these pa-
tients?
DR. ANDRIOLE: In our patients treated with intrathecal amphotericin it was difficult
to sort out whether there was added benefit to the intrathecal route [2], simply
because most of the patients who received amphotericin B intrathecally were also
receiving medication intravenously. In one patient that I am aware of, amphotericin
B intrathecally was used alone because ofsystemic side effects to an earlier course of
intravenous amphotericin. The patient seemed to do well. However, I think that this
one patient does not permit any conclusions about the relative efficacy ofintrathecal
amphotericin in this disease.
DR. COLEMAN: Let me complete the description of the patient's hospital course. His
repeat lumbar puncture results revealed a negative India ink prep, acryptococcal an-
tigen titer of 1:16, and a positive CSF culture for Cryptococcusneoformans. We em-
barked on a regimen of 5-fluorocytosine and amphotericin B. We isolated Cryp-
tococcus neoformans and using tube dilution methods determined a minimum in-
hibitory concentration (MIC) of5-fluorocytosine. The MIC of5-fluorocytosine was
0.488 /g/ml, which was considered a good level of activity against the organism.
This test was performed because of the observation that a high level of
5-fluorocytosine resistance by Cryptococcus neoformans is associated with an-
tagonism between it and amphotericin in vitro [3]. We were also interested in this
result to precisely quantitate the need for combination therapy in this particular pa-
tient. The patient is on 150 mg/kg/day of 5-fluorocytosine and is now receiving
0.5 mg/kg/day of amphotericin. The higher dose of amphotericin was employed
because of the large mass lesion present in the pons, and because ofthe concerns ex-
pressed by Dr. Andriole, that the dose of amphotericin used in the comparative
study was low. The plan for this patient is to continue the combination treatment
regimen following the usual hematologic and renal parameters.The role of serial CT
scans in terminating treatment is unclear. A recent review from UCLA [4] sum-
marized their experience in treating patients with crytococcal CNS mass lesions.
Three of the patients were successfully treated with medical regimens. The cephalic
CT scan was useful in prompting a change in antifungal therapy when new lesions
were discovered. In addition, successfully treated patients had gradual decrease in
the size of their mass lesions on CT scan. Reported cases of cryptoccal intracerebral
mass lesions number under 100. Therefore prospective therapeutic trials will be dif-
56AN UNUSUAL PONTINE MASS LESION 57
ficult to conduct. As noninvasive diagnostic techniques achieve greater sensitivity
perhaps greater numbers of cryptococcal intracerebral mass lesions with or without
associated meningitis will be discovered.
DR. ROOT: Dr. Andriole, can you comment on the role of ketoconazole in the treat-
ment of this infection?
DR. ANDRIOLE: I have no experience with the use of this agent although animal
studies suggest that it may be effective. I am unaware of any major clinical trials to
determine its utility for the treatment of cryptococcal meningitis. I would urge that
in considering treatment regimens for fungal disease one adopt a strategy of long-
term follow-up. We have seen patients who were apparently cured, only to relapse
some years later, and this complicates the interpretation of treatment successes
published in the literature.
DR ROOT: My und&rstanding is that penetration of miconazole into the CSF is quite
poor; however, ketoconazole does have adequate penetration into the CSF and may
have some role in the treatment ofthis infection. There have been cases ofsuccessful
treatment of cryptococcal infection with miconazole, but its inadequate CSF
penetration would probably limit its utility in this setting. Dr. Andriole, what would
you follow in these patients to guide you as to when to terminate therapy?
DR. ANDRIOLE: We have, at various times, had some enthusiasm for a variety of CSF
parameters as indicators for disease activity. However, I have become impressed
that it is difficult to rely on any single measurement to decide when to terminate
therapy. Clearly one would like to see a marked reduction in the inflammatory
response in the spinal fluid and clearance of the cryptococcal antigen.
DR. ROOT: What does the cryptococcal antigen tell you?
DR. ANDRIOLE: One can detect cryptococcal antigens in the absence of live
organisms. We have often also seen patients with positive India ink preps whose
CSF was injected into mice and did not cause alethal effect. This would suggest that
the organisms seen were not alive. We used two negative mouse inoculation tests to
warrant the discontinuation oftreatment. I think that's the reason why our duration
of treatment was longer than that reported in other series.
DR. COLEMAN: The patient was discharged after receiving a total oftwo grams ofam-
photericin B. The patient's neurological deficit did not improve. A follow-up CT
scan two months after discharge was unchanged from that obtained at the time of
initial diagnosis.
Editors'comment: The discussants have framed some important questions regarding
the treatment ofcryptococcal lesions ofthe central nervous system. Dr. Andriole ad-
vises caution before advocating the use of5-fluorocytosine in combination with am-
photericin as opposed to amphotericin alone for this disease. Not only does he ques-
tion efficacy but voices concern about potential toxicity. Should combination
therapy prove effective and safe, he suggests its chief benefit may be to shorten the
prolonged treatment schedule required for treatment of this disease.
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